publication . Article . 2015

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations

Open Access Russian
  • Published: 01 Jun 2015 Journal: Onkogematologiâ, volume 10, issue 2, pages 37-45 (issn: 1818-8346, Copyright policy)
  • Publisher: ABV-press
Abstract
<p>Neutropenia and associated infection, resulting in hospitalization and use of antibiotics, has a negative effect on chemotherapy. The need to reduce the dose of cytotoxic drugs during neutropenia leads to lower survival rates in patients with hematological malignancies and solid tumors. Since 1990s myelocytokines – proteins that accelerate neutrophil recovery after cytostatic chemotherapy and reduce the risk of infection – is widely used in the clinical practice. The use of these drugs can support the planned dose intensity of chemotherapy and improves the treatment efficacy. The disadvantages of these drugs include the need for their daily parenteral adminis...
Persistent Identifiers
Subjects
free text keywords: chemotherapy, dose intensity, toxicity, neutropenia, granulocyte colony stimulating factor, pegfilgrastim, lipegfilgrastim, Lonkvex, lcsh:Diseases of the blood and blood-forming organs, lcsh:RC633-647.5, Medicine, business.industry, business, Breast cancer, medicine.disease, Doxorubicin, medicine.drug, Docetaxel, Surgery, medicine.medical_specialty, medicine.medical_treatment, Tolerability, Oncology, Internal medicine
Any information missing or wrong?Report an Issue